中华核医学与分子影像杂志
中華覈醫學與分子影像雜誌
중화핵의학여분자영상잡지
Chinese Journal of Nuclear Medicine and Molecular Imaging
2012年
2期
100-104
,共5页
宋卫香%王志刚%张群霞%骆杰%牛诚诚%游玉芳%张花
宋衛香%王誌剛%張群霞%駱傑%牛誠誠%遊玉芳%張花
송위향%왕지강%장군하%락걸%우성성%유옥방%장화
造影剂%紫杉醇%Herceptin%超声检查%细胞学%乳腺肿瘤
造影劑%紫杉醇%Herceptin%超聲檢查%細胞學%乳腺腫瘤
조영제%자삼순%Herceptin%초성검사%세포학%유선종류
Contrast media%Paclitaxel%Herceptin%Ultrasonography%Cytology%Breast neoplasms
目的 探讨携紫杉醇(Pac)和注射用曲妥珠单克隆抗体(Herceptin)高分子造影剂(Pac-PLGA-HER)联合超声体外寻靶能力及显影效果.方法 通过双乳化法和碳二亚胺法制备载Pac靶向高分子造影剂.将MCF-7细胞种植于12个培养皿中,培养24 h,分为4组,每组3个:非靶向造影剂组(Pac-PLGA组)、靶向造影剂组(Pac-PLGA-HER组)、靶向造影剂+超声组(Pac-PLGA-HER+超声组)和抗体封闭组.在激光共聚焦显微镜下对比观察高分子造影剂与细胞的结合能力.观察体外显影效果,并用DFY型定量仪进行定量,采用独立样本t检验进行统计学分析.结果 靶向载Pac高分子造影剂平均粒径为(596±12) nm,体外寻靶能力实验显示靶向载Pac高分子造影剂可与MCF-7细胞大量结合.体外显影实验示靶向与非靶向载Pac高分子造影剂平均声强分别为(134.50±10.19)和(135.11±11.49) dB,平均灰阶分别为147.83±11.12和148.50±12.63,两者比较差异均无统计学意义(t均为-0.097,P均＞0.05).结论 携Pac和Herceptin的高分子造影剂对高表达HER2的人乳腺癌MCF-7有较强的结合能力,在体外显影实验中有较好的显影效果.
目的 探討攜紫杉醇(Pac)和註射用麯妥珠單剋隆抗體(Herceptin)高分子造影劑(Pac-PLGA-HER)聯閤超聲體外尋靶能力及顯影效果.方法 通過雙乳化法和碳二亞胺法製備載Pac靶嚮高分子造影劑.將MCF-7細胞種植于12箇培養皿中,培養24 h,分為4組,每組3箇:非靶嚮造影劑組(Pac-PLGA組)、靶嚮造影劑組(Pac-PLGA-HER組)、靶嚮造影劑+超聲組(Pac-PLGA-HER+超聲組)和抗體封閉組.在激光共聚焦顯微鏡下對比觀察高分子造影劑與細胞的結閤能力.觀察體外顯影效果,併用DFY型定量儀進行定量,採用獨立樣本t檢驗進行統計學分析.結果 靶嚮載Pac高分子造影劑平均粒徑為(596±12) nm,體外尋靶能力實驗顯示靶嚮載Pac高分子造影劑可與MCF-7細胞大量結閤.體外顯影實驗示靶嚮與非靶嚮載Pac高分子造影劑平均聲彊分彆為(134.50±10.19)和(135.11±11.49) dB,平均灰階分彆為147.83±11.12和148.50±12.63,兩者比較差異均無統計學意義(t均為-0.097,P均＞0.05).結論 攜Pac和Herceptin的高分子造影劑對高錶達HER2的人乳腺癌MCF-7有較彊的結閤能力,在體外顯影實驗中有較好的顯影效果.
목적 탐토휴자삼순(Pac)화주사용곡타주단극륭항체(Herceptin)고분자조영제(Pac-PLGA-HER)연합초성체외심파능력급현영효과.방법 통과쌍유화법화탄이아알법제비재Pac파향고분자조영제.장MCF-7세포충식우12개배양명중,배양24 h,분위4조,매조3개:비파향조영제조(Pac-PLGA조)、파향조영제조(Pac-PLGA-HER조)、파향조영제+초성조(Pac-PLGA-HER+초성조)화항체봉폐조.재격광공취초현미경하대비관찰고분자조영제여세포적결합능력.관찰체외현영효과,병용DFY형정량의진행정량,채용독립양본t검험진행통계학분석.결과 파향재Pac고분자조영제평균립경위(596±12) nm,체외심파능력실험현시파향재Pac고분자조영제가여MCF-7세포대량결합.체외현영실험시파향여비파향재Pac고분자조영제평균성강분별위(134.50±10.19)화(135.11±11.49) dB,평균회계분별위147.83±11.12화148.50±12.63,량자비교차이균무통계학의의(t균위-0.097,P균＞0.05).결론 휴Pac화Herceptin적고분자조영제대고표체HER2적인유선암MCF-7유교강적결합능력,재체외현영실험중유교호적현영효과.
Objective To further explore the affinity of paclitaxel-loaded and trastuzumab ( Herceptin) -targeted poly ( lactic-co-glycolic acid,PLGA) -COOH ultrasound contrast agent (Pac-PLGA-HER)for human breast cancer cell line MCF-7 and study their effect on ultrasound imaging in vitro.Methods Paclitaxel-loaded PLGA-COOH ultrasound contrast agents (Pac-PLGA) were prepared by the double emulsion technique and conjugated with Herceptin monoclonal antibody by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC)/N-hyalroxysuccinimide (NHS).MCF-7 cells were plated in culture dishes for 24 h and divided into 4 groups with 3 dishes in each group,i.e.Pac-PLGA group,Pac-PLGA-HER group,ultrasound + Pac-PLGA-HER group and antibody blocking group.Binding of polymer ultrasound contrast agents to MCF-7 cells was observed by laser scanning confocal microscopy.In vitro experiments were employed to study the effects of Pac-PLGA-HER on the enhancement of ultrasound imaging as compared with Pac-PLGA,the control group.Independent samples t-test was used for statistical analysis with the help of DFY.Results The average diameter of Pac-PLGA-HER was (596 ± 12) nm.In the in vitro targeting study,a number of Pac-PLGA-HER bound with MCF-7 cells tightly; while,no conjugation was observed in the control group.During in vitro ultrasound imaging,the average sound intensity of Pac-PLGA-HER and Pac-PLGA was (134.50 ± 10.19) and (135.11 ±11.49) dB (t =-0.097,P＞0.05) and the average grey scale was 147.83 ± 11.12 and 148.50 ± 12.63 (t =-0.097,P ＞0.05 ),respectively.There was no difference between the two.Conclusion Pac-PLGA-HER could bind to high HER2-expressing MCF-7 cells specifically and effectively and was an effective ultrasound contrast agent in vitro.
